Sikander Ailawadhi

Mayo Clinic
Division of Hematology-Oncology
4500 San Pablo Rd.
Jacksonville, FL
USA 32224
622 Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia
1606 Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
1911 Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome
3232 Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect® MM Registry
3244 Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines
4138 Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)
4141 Depth of Response in Waldenstrom Macroglobulinemia
4764 Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care
4765 Trends in the Utilization of Radiation Therapy (XRT) Among Patients with Non-Hodgkin's Lymphoma (NHL) in the United States (US)
4852 Impact of Depression or Anxiety on Opioid and Benzodiazepine Use in Hospitalized Hematopoietic Stem Cell Transplantation (HSCT) Recipients
4861 Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States
4867 Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities
4868 Sociodemographic Profile and Outcomes of Patients with Non-Diffuse Large B-Cell Lymphoma (non-DLBCL) Treated at Minority-Predominant Facilities in the United States
4869 Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL)